ResearcherUniversité Paris CitéActive in the last 2 years
Alix Portal
Matched on OpenAlex author ID A5044504255. Sources: OpenAlex.
Their work
- Papers
- 4
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 20
2014: 1 paper · 2015: 1 paper · 2016: 1 paper · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: none · 2025: 1 paper
Papers 4
- Predictive and prognostic factors of efficacy of third-line chemotherapy in patients with unresectable pancreatic cancer: a cohort-based study. Co-author DOI 10.1093/oncolo/oyaf125↗
- Reply to the comment on 'Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre coh… Co-author DOI 10.1038/bjc.2016.70↗
- Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort. Co-author DOI 10.1038/bjc.2015.328↗
- Sustained response with gemcitabine plus Nab-paclitaxel after folfirinox failure in metastatic pancreatic cancer: report of an effective new strategy. Co-author DOI 10.1016/j.clinre.2014.01.005↗
Closest collaborators
The 20 strongest of 20 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Julien Taı̈eb · 4 shared papers, 2014–2025 · strength 0.33
- Paper Predictive and prognostic factors of efficacy of third-line chemotherapy in patients with unresectable pancreatic cance… DOI 10.1093/oncolo/oyaf125↗
- Paper Reply to the comment on 'Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox fail… DOI 10.1038/bjc.2016.70↗
- Paper Sustained response with gemcitabine plus Nab-paclitaxel after folfirinox failure in metastatic pancreatic cancer: repor… DOI 10.1016/j.clinre.2014.01.005↗
- Simon Pernot · 4 shared papers, 2014–2025 · strength 0.33
- Paper Predictive and prognostic factors of efficacy of third-line chemotherapy in patients with unresectable pancreatic cance… DOI 10.1093/oncolo/oyaf125↗
- Paper Reply to the comment on 'Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox fail… DOI 10.1038/bjc.2016.70↗
- Paper Sustained response with gemcitabine plus Nab-paclitaxel after folfirinox failure in metastatic pancreatic cancer: repor… DOI 10.1016/j.clinre.2014.01.005↗
- Jean‐Baptiste Bachet · 3 shared papers, 2015–2025 · strength 0.28
- Paper Predictive and prognostic factors of efficacy of third-line chemotherapy in patients with unresectable pancreatic cance… DOI 10.1093/oncolo/oyaf125↗
- Paper Reply to the comment on 'Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox fail… DOI 10.1038/bjc.2016.70↗
- Paper Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective … DOI 10.1038/bjc.2015.328↗
- Franck Bonnetain · 2 shared papers, 2015–2025 · strength 0.20
- Paper Predictive and prognostic factors of efficacy of third-line chemotherapy in patients with unresectable pancreatic cance… DOI 10.1093/oncolo/oyaf125↗
- Paper Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective … DOI 10.1038/bjc.2015.328↗
- Laëtitia Dahan · 2 shared papers, 2015–2025 · strength 0.20
- Paper Predictive and prognostic factors of efficacy of third-line chemotherapy in patients with unresectable pancreatic cance… DOI 10.1093/oncolo/oyaf125↗
- Paper Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective … DOI 10.1038/bjc.2015.328↗
- Lysiane Marthey · 2 shared papers, 2015–2025 · strength 0.20
- Paper Predictive and prognostic factors of efficacy of third-line chemotherapy in patients with unresectable pancreatic cance… DOI 10.1093/oncolo/oyaf125↗
- Paper Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective … DOI 10.1038/bjc.2015.328↗
- Pascal R. Hammel · 2 shared papers, 2015–2025 · strength 0.20
- Paper Predictive and prognostic factors of efficacy of third-line chemotherapy in patients with unresectable pancreatic cance… DOI 10.1093/oncolo/oyaf125↗
- Paper Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective … DOI 10.1038/bjc.2015.328↗
- David Tougeron · 2 shared papers, 2015–2025 · strength 0.20
- Paper Predictive and prognostic factors of efficacy of third-line chemotherapy in patients with unresectable pancreatic cance… DOI 10.1093/oncolo/oyaf125↗
- Paper Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective … DOI 10.1038/bjc.2015.328↗
- Romain Coriat · 2 shared papers, 2015–2025 · strength 0.20
- Paper Predictive and prognostic factors of efficacy of third-line chemotherapy in patients with unresectable pancreatic cance… DOI 10.1093/oncolo/oyaf125↗
- Paper Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective … DOI 10.1038/bjc.2015.328↗
- Raëf Abdallah · 1 shared paper, 2025 · strength 0.16
- Anne‐Laure Pointet · 1 shared paper, 2025 · strength 0.16
- Jean–Marc Phelip · 1 shared paper, 2025 · strength 0.16
- Camille Evrard · 1 shared paper, 2025 · strength 0.16
- Émilie Soularue · 1 shared paper, 2025 · strength 0.16
- Isabelle Trouilloud · 1 shared paper, 2025 · strength 0.16
- Dominique Béchade · 1 shared paper, 2025 · strength 0.16
- Nicolas Williet · 1 shared paper, 2025 · strength 0.16
- Philippe R Rougier · 1 shared paper, 2014 · strength 0.04
- Aziz Zaanan · 1 shared paper, 2014 · strength 0.04
- Christelle de la Fouchardière · 1 shared paper, 2015 · strength 0.04
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.